A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression
Janssen Research & Development, LLC
View at source ↗Clinical trial
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Brief summary
The purpose of this study is to assess the safety and tolerability of esketamine nasal spray in participants with treatment-resistant depression (TRD).
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Trial details
- acronym
- SUSTAIN-3
- status
- COMPLETED
- phase
- PHASE3
- study type
- INTERVENTIONAL
- enrollment
- 1148
- sponsor
- Janssen Research & Development, LLC
- conditions
- Depressive Disorder, Treatment-Resistant
- interventions
- DRUG: Esketamine Nasal Spray
- start date
- 2016-06-09
- start date type
- ACTUAL
- primary completion date
- 2022-12-30
- has results
- true
- data source
- ClinicalTrials.gov
- data processed
- 2026-10-29T09:00:05
- modifications
- selected fields only; whitespace normalized; brief summary truncated to 2,000 characters
Record
- Archive ID
- nct:NCT02782104
- Published
- May 25, 2016
- Updated
- Apr 29, 2025
- Venue
- ClinicalTrials.gov
- ClinicalTrials.gov
- NCT02782104
- Categories
- Depressive Disorder, Treatment-Resistant
- License
- ClinicalTrials.gov terms (attribution, processing date, modifications noted)
- Provenance
- clinicaltrials